WO2002060897A3 - Process for making substituted 8-arylquinolinium benzenesulfonate - Google Patents

Process for making substituted 8-arylquinolinium benzenesulfonate Download PDF

Info

Publication number
WO2002060897A3
WO2002060897A3 PCT/US2001/048385 US0148385W WO02060897A3 WO 2002060897 A3 WO2002060897 A3 WO 2002060897A3 US 0148385 W US0148385 W US 0148385W WO 02060897 A3 WO02060897 A3 WO 02060897A3
Authority
WO
WIPO (PCT)
Prior art keywords
arylquinolinium
benzenesulfonate
making substituted
methylsulfonyl
phenyl
Prior art date
Application number
PCT/US2001/048385
Other languages
French (fr)
Other versions
WO2002060897A2 (en
Inventor
Richard Desmond
David A Conlon
Antoinette Drahus
Guo-Jie Ho
Brenda Pipik
Carl Leblond
Anant Vailaya
Original Assignee
Merck & Co Inc
Richard Desmond
David A Conlon
Antoinette Drahus
Guo-Jie Ho
Brenda Pipik
Carl Leblond
Anant Vailaya
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2002561465A priority Critical patent/JP4141838B2/en
Priority to PL01361767A priority patent/PL361767A1/en
Application filed by Merck & Co Inc, Richard Desmond, David A Conlon, Antoinette Drahus, Guo-Jie Ho, Brenda Pipik, Carl Leblond, Anant Vailaya filed Critical Merck & Co Inc
Priority to BR0116231-4A priority patent/BR0116231A/en
Priority to EP01994243A priority patent/EP1345933B1/en
Priority to HU0302457A priority patent/HUP0302457A3/en
Priority to US10/433,538 priority patent/US6835837B2/en
Priority to EA200300707A priority patent/EA005864B1/en
Priority to IL15617601A priority patent/IL156176A0/en
Priority to AU2002246665A priority patent/AU2002246665B2/en
Priority to MXPA03005571A priority patent/MXPA03005571A/en
Priority to KR1020037008279A priority patent/KR100776927B1/en
Priority to UA2003076826A priority patent/UA74862C2/en
Priority to AT01994243T priority patent/ATE298335T1/en
Priority to SK769-2003A priority patent/SK7692003A3/en
Priority to NZ526143A priority patent/NZ526143A/en
Priority to DE60111648T priority patent/DE60111648T2/en
Priority to CA002431559A priority patent/CA2431559A1/en
Publication of WO2002060897A2 publication Critical patent/WO2002060897A2/en
Publication of WO2002060897A3 publication Critical patent/WO2002060897A3/en
Priority to HR20030507A priority patent/HRP20030507A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention is directed to a process to synthesize 6-[1-methyl-1-(methylsulfonyl)ethyl]-8-[3(E)-2-[3-methyl-1,2,4-oxadizol-5-yl]-2-[4-(methylsulfonyl)phenyl]ethenyl]phenyl]quinoline and its benzenesulfonic acid salt.
PCT/US2001/048385 2000-12-20 2001-12-14 Process for making substituted 8-arylquinolinium benzenesulfonate WO2002060897A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
KR1020037008279A KR100776927B1 (en) 2000-12-20 2001-12-14 Process for making substituted 8-arylquinolinium benzenesulfonate
MXPA03005571A MXPA03005571A (en) 2000-12-20 2001-12-14 Process for making substituted 8-arylquinolinium benzenesulfonate.
UA2003076826A UA74862C2 (en) 2000-12-20 2001-12-14 Methods for producing 8-aryl quinoline and its benzenesulfonic acid salts
PL01361767A PL361767A1 (en) 2000-12-20 2001-12-14 Process for making substituted 8-arylquinolinium benzenesulfonate
HU0302457A HUP0302457A3 (en) 2000-12-20 2001-12-14 Process for making substituted 8-arylquinolinium benzenesulfonate
US10/433,538 US6835837B2 (en) 2000-12-20 2001-12-14 Process for making substituted 8-arylquinolinium benzenesulfonate
EA200300707A EA005864B1 (en) 2000-12-20 2001-12-14 Process for making substituted 8-arylquinolinium benzenesulfonate
IL15617601A IL156176A0 (en) 2000-12-20 2001-12-14 Process for making substituted 8-arylquinolinium benzenesulfonate
AU2002246665A AU2002246665B2 (en) 2000-12-20 2001-12-14 Process for making substituted 8-arylquinolinium benzenesulfonate
JP2002561465A JP4141838B2 (en) 2000-12-20 2001-12-14 Process for producing substituted 8-arylquinolinium benzenesulfonates
EP01994243A EP1345933B1 (en) 2000-12-20 2001-12-14 Process for making substituted 8-arylquinolinium benzenesulfonate
BR0116231-4A BR0116231A (en) 2000-12-20 2001-12-14 Method of forming a reaction product mixture
AT01994243T ATE298335T1 (en) 2000-12-20 2001-12-14 METHOD FOR PRODUCING SUBSTITUTED 8-ARYLCINOLINIUM BENZENESULFONATE
SK769-2003A SK7692003A3 (en) 2000-12-20 2001-12-14 Process for making substituted 8-arylquinolinium benzenesulfonate
NZ526143A NZ526143A (en) 2000-12-20 2001-12-14 Process for making substituted 8-arylquinolinium benzenesulfonate
DE60111648T DE60111648T2 (en) 2000-12-20 2001-12-14 Process for the preparation of substituted 8-arylquinolinium benzenesulfonate
CA002431559A CA2431559A1 (en) 2000-12-20 2001-12-14 Process for making substituted 8-arylquinolinium benzenesulfonate
HR20030507A HRP20030507A2 (en) 2000-12-20 2003-06-18 Process for making substituted 8-arylquinolinium benzensulfonate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25679900P 2000-12-20 2000-12-20
US60/256,799 2000-12-20

Publications (2)

Publication Number Publication Date
WO2002060897A2 WO2002060897A2 (en) 2002-08-08
WO2002060897A3 true WO2002060897A3 (en) 2003-05-08

Family

ID=22973621

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/048385 WO2002060897A2 (en) 2000-12-20 2001-12-14 Process for making substituted 8-arylquinolinium benzenesulfonate

Country Status (26)

Country Link
US (1) US6835837B2 (en)
EP (1) EP1345933B1 (en)
JP (1) JP4141838B2 (en)
KR (1) KR100776927B1 (en)
CN (1) CN1211383C (en)
AR (1) AR035932A1 (en)
AT (1) ATE298335T1 (en)
AU (1) AU2002246665B2 (en)
BR (1) BR0116231A (en)
CA (1) CA2431559A1 (en)
CZ (1) CZ20031620A3 (en)
DE (1) DE60111648T2 (en)
EA (1) EA005864B1 (en)
EG (1) EG23966A (en)
ES (1) ES2242787T3 (en)
HR (1) HRP20030507A2 (en)
HU (1) HUP0302457A3 (en)
IL (1) IL156176A0 (en)
MX (1) MXPA03005571A (en)
NZ (1) NZ526143A (en)
PL (1) PL361767A1 (en)
RS (1) RS50474B (en)
SK (1) SK7692003A3 (en)
TW (1) TWI243171B (en)
UA (1) UA74862C2 (en)
WO (1) WO2002060897A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307863D0 (en) * 2003-04-04 2003-05-14 Merck Sharp & Dohme Therapeutic treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4006137A (en) * 1975-08-21 1977-02-01 E. R. Squibb & Sons, Inc. 2-Ethenyl imidazolium derivatives
WO1995035283A1 (en) * 1994-06-21 1995-12-28 Celltech Therapeutics Limited Tri-substituted phenyl derivatives useful as pde iv inhibitors
WO1999037622A1 (en) * 1998-01-26 1999-07-29 Eisai Co., Ltd. Nitrogenous heterocyclic derivatives and medicine thereof
WO2001046151A1 (en) * 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6740566B2 (en) 1999-09-17 2004-05-25 Advanced Micro Devices, Inc. Ultra-thin resist shallow trench process using high selectivity nitride etch
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6740666B2 (en) * 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4006137A (en) * 1975-08-21 1977-02-01 E. R. Squibb & Sons, Inc. 2-Ethenyl imidazolium derivatives
WO1995035283A1 (en) * 1994-06-21 1995-12-28 Celltech Therapeutics Limited Tri-substituted phenyl derivatives useful as pde iv inhibitors
WO1999037622A1 (en) * 1998-01-26 1999-07-29 Eisai Co., Ltd. Nitrogenous heterocyclic derivatives and medicine thereof
EP1052254A1 (en) * 1998-01-26 2000-11-15 Eisai Co., Ltd. Nitrogenous heterocyclic derivatives and medicine thereof
WO2001046151A1 (en) * 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RANGNEKAR D W ET AL: "Synthesis and application of 2-styryl-6(7)-bromothiazolo[4,5-b]quinox aline based fluorescent dye chromophores: Part 2", DYES AND PIGMENTS, ELSEVIER APPLIED SCIENCE PUBLISHERS. BARKING, GB, vol. 45, no. 2, May 2000 (2000-05-01), pages 87 - 96, XP004197559, ISSN: 0143-7208 *

Also Published As

Publication number Publication date
TWI243171B (en) 2005-11-11
CA2431559A1 (en) 2002-08-08
NZ526143A (en) 2004-05-28
DE60111648D1 (en) 2005-07-28
PL361767A1 (en) 2004-10-04
EG23966A (en) 2008-02-13
HRP20030507A2 (en) 2005-06-30
US6835837B2 (en) 2004-12-28
KR20030063443A (en) 2003-07-28
MXPA03005571A (en) 2003-10-06
DE60111648T2 (en) 2006-05-11
AU2002246665B2 (en) 2006-07-20
EP1345933A2 (en) 2003-09-24
ES2242787T3 (en) 2005-11-16
CZ20031620A3 (en) 2003-08-13
AR035932A1 (en) 2004-07-28
HUP0302457A3 (en) 2009-10-28
JP2004518690A (en) 2004-06-24
WO2002060897A2 (en) 2002-08-08
US20040044213A1 (en) 2004-03-04
UA74862C2 (en) 2006-02-15
HUP0302457A2 (en) 2003-11-28
KR100776927B1 (en) 2007-11-20
YU48303A (en) 2006-05-25
BR0116231A (en) 2004-03-02
EP1345933B1 (en) 2005-06-22
SK7692003A3 (en) 2003-10-07
EA200300707A1 (en) 2003-10-30
CN1483032A (en) 2004-03-17
ATE298335T1 (en) 2005-07-15
EA005864B1 (en) 2005-06-30
RS50474B (en) 2010-03-02
CN1211383C (en) 2005-07-20
JP4141838B2 (en) 2008-08-27
IL156176A0 (en) 2003-12-23

Similar Documents

Publication Publication Date Title
WO2000047583A8 (en) Cyclic substituted fused pyrrolocarbazoles and isoindolones
HK1041265B (en) Process for the production of tert-butyl(e)-(6-(2-(4-(4-fluorophenyl-6-isopropyl-2-(methyl(methylsulfonyl)amino)pyrimidin-5-yl)vinyl(4r,6s)-2,2-dimethyl(1,3)dioxan-4-yl)acetate
WO2006019668A3 (en) (1s,5s)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
NO20010684D0 (en) Substituted 1,8-Naphthyridin-4 (1H) -one as phosphodiesterase 4 inhibitors
CA2341291A1 (en) Pyridine ketones useful as herbicides
WO2002020489A3 (en) QUINOLINE INHIBITORS OF cGMP PHOSPHODIESTERASE
WO2003006425A3 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2001017973A3 (en) Novel herbicides
NO20006039D0 (en) Process for Preparation of 4-Carboxyamino-2-Substituted-1,2,3,4-Tetrahydroquinoline
WO2002060897A3 (en) Process for making substituted 8-arylquinolinium benzenesulfonate
IL153662A0 (en) Process for the preparation of 4,6-dimethoxy-2- (methylsulfonyl)-1,3-pyrimidine
WO2003024400A3 (en) Process for the preparation of 1,5-diarylpyrazoles
AU2002359160A1 (en) PIPAZOLO (1,5-a) PYRIMIDINE DERIVATIVES AS MODULATORS OF PPAR
NO20005424L (en) Process for the preparation of 1,3-disubstituted-4-oxocyclic ureas
EA199900458A3 (en) Process for intermediates for the manufacture of pyridine-2,3-dicarboxylate compounds
WO2006008641A8 (en) Hair growth promoting agents
AU2003303098A1 (en) Process for the preparation of 2-aminomethylpyridine derivative
WO2004092121A3 (en) Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones
EP1065202A4 (en) 6-(alpha-fluoroalkyl)-4-pyrimidones and process for producing the same
PT1133495E (en) SEMI-HYDROCHLORIDE OF 8-CYANO-1-CYCLOPROPYL-7- (1S, 6S-2,8-DIAZABICYCLO-4,3,0-NANO-8-YL) -6-FLUORO-1,4-DIHYDRO-4 -OXO-3-KINOLINOCARBOXYLIC ACID
EP0924198A3 (en) 3-Mercapto-2-alkyl-alkan-1-ols and their use as perfuming and flavouring agents
AU5710898A (en) Certain 3-{2,4-disubstituted-5-(substituted amino)phenyl}-1-substituted-6-trifluoromethyl-2,4-(1(h),3(h) )-pyrimidinedione derivatives as herbicides
CA2328832A1 (en) Processes for preparing pesticidal intermediates
NO20006624D0 (en) Process for the preparation of alkaline aqueous cleaners in the form of creams
AU2992800A (en) Process for the preparation of 6-(perfluoroalkyl)uracil compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-483/03

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10433538

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 526143

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 156176

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002246665

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001994243

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002561465

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PV2003-1620

Country of ref document: CZ

Ref document number: 2431559

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 7692003

Country of ref document: SK

Ref document number: P20030507A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/005571

Country of ref document: MX

Ref document number: 1020037008279

Country of ref document: KR

Ref document number: 018209149

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1098/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200300707

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020037008279

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2003-1620

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2001994243

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 526143

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 526143

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001994243

Country of ref document: EP